JP2024500242A5 - - Google Patents
Info
- Publication number
- JP2024500242A5 JP2024500242A5 JP2023538891A JP2023538891A JP2024500242A5 JP 2024500242 A5 JP2024500242 A5 JP 2024500242A5 JP 2023538891 A JP2023538891 A JP 2023538891A JP 2023538891 A JP2023538891 A JP 2023538891A JP 2024500242 A5 JP2024500242 A5 JP 2024500242A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216800.1 | 2020-12-23 | ||
| EP20216800 | 2020-12-23 | ||
| PCT/EP2021/087495 WO2022136642A1 (en) | 2020-12-23 | 2021-12-23 | Tumor-specific claudin 18.2 antibody-drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500242A JP2024500242A (ja) | 2024-01-05 |
| JPWO2022136642A5 JPWO2022136642A5 (https=) | 2025-01-17 |
| JP2024500242A5 true JP2024500242A5 (https=) | 2025-01-17 |
Family
ID=73856974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538891A Pending JP2024500242A (ja) | 2020-12-23 | 2021-12-23 | 腫瘍特異的クローディン１８．２抗体と薬物との複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240100180A1 (https=) |
| EP (1) | EP4267194A1 (https=) |
| JP (1) | JP2024500242A (https=) |
| KR (1) | KR20230124037A (https=) |
| CN (1) | CN116635085A (https=) |
| AU (1) | AU2021405049A1 (https=) |
| CA (1) | CA3199830A1 (https=) |
| CL (1) | CL2023001800A1 (https=) |
| IL (1) | IL302894A (https=) |
| MX (1) | MX2023007644A (https=) |
| PE (1) | PE20231561A1 (https=) |
| TW (1) | TW202241519A (https=) |
| WO (1) | WO2022136642A1 (https=) |
| ZA (1) | ZA202305221B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069738A1 (en) * | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US20260071003A1 (en) | 2022-09-01 | 2026-03-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| CN115368435B (zh) * | 2022-09-06 | 2025-04-18 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物连接子set0568的合成方法 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN119139489A (zh) * | 2023-06-16 | 2024-12-17 | 信达生物制药(苏州)有限公司 | 靶向Claudin18.2的抗体-药物偶联物用于治疗实体瘤的方法 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050213A1 (en) | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015659A2 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| CN102159248B (zh) * | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2869851A1 (en) * | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| SG11201705041WA (en) * | 2014-12-23 | 2017-07-28 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| JP7398380B2 (ja) | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| US11485782B2 (en) * | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| SG11202007074PA (en) | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN111867630B (zh) | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| US11505618B2 (en) | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| CN112770723B (zh) | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| WO2020038404A1 (zh) | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
| EP3878863A4 (en) | 2018-08-27 | 2022-06-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE |
| US20220033491A1 (en) | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
| BR112021007690A2 (pt) | 2018-10-22 | 2021-08-10 | Shanghai GenBase Biotechnology Co., Ltd. | anticorpo anti-cldn18.2 e uso do mesmo |
| CN113227135B (zh) | 2018-12-28 | 2025-03-21 | 斯帕克斯治疗公司 | 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法 |
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CN113227146B (zh) | 2018-12-28 | 2024-03-01 | 南京金斯瑞生物科技有限公司 | 密蛋白18.2结合部分和其用途 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| MX2021011489A (es) | 2019-04-01 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. |
| EP4069738A1 (en) * | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| CN114901365B (zh) * | 2019-12-23 | 2025-07-15 | 斯迪安生物技术公司 | 肿瘤特异性密蛋白18.2抗体 |
| CN113929780A (zh) | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
-
2021
- 2021-12-23 CA CA3199830A patent/CA3199830A1/en active Pending
- 2021-12-23 KR KR1020237024767A patent/KR20230124037A/ko not_active Withdrawn
- 2021-12-23 JP JP2023538891A patent/JP2024500242A/ja active Pending
- 2021-12-23 EP EP21847946.7A patent/EP4267194A1/en not_active Withdrawn
- 2021-12-23 PE PE2023001921A patent/PE20231561A1/es unknown
- 2021-12-23 WO PCT/EP2021/087495 patent/WO2022136642A1/en not_active Ceased
- 2021-12-23 CN CN202180085938.6A patent/CN116635085A/zh active Pending
- 2021-12-23 MX MX2023007644A patent/MX2023007644A/es unknown
- 2021-12-23 AU AU2021405049A patent/AU2021405049A1/en not_active Abandoned
- 2021-12-23 US US18/269,240 patent/US20240100180A1/en active Pending
- 2021-12-23 IL IL302894A patent/IL302894A/en unknown
- 2021-12-23 TW TW110148442A patent/TW202241519A/zh unknown
-
2023
- 2023-05-11 ZA ZA2023/05221A patent/ZA202305221B/en unknown
- 2023-06-16 CL CL2023001800A patent/CL2023001800A1/es unknown